Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Michael, Wernecke"'
Autor:
Rachel P. Ogilvie, J. Bradley Layton, Patricia C. Lloyd, Yixin Jiao, Djeneba Audrey Djibo, Hui Lee Wong, Joann F. Gruber, Ron Parambi, Jie Deng, Michael Miller, Jennifer Song, Lisa B. Weatherby, Lauren Peetluk, An-Chi Lo, Kathryn Matuska, Michael Wernecke, Christine L. Bui, Tainya C. Clarke, Sylvia Cho, Elizabeth J. Bell, Grace Yang, Kandace L. Amend, Richard A. Forshee, Steven A. Anderson, Cheryl N. McMahill-Walraven, Yoganand Chillarige, Mary S. Anthony, John D. Seeger, Azadeh Shoaibi
Publikováno v:
BMC Pediatrics, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background COVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. This study’s objective was to estimate the effectiveness of receiving a complete pr
Externí odkaz:
https://doaj.org/article/a71040a255aa47ef99a2668dec27e3e6
Autor:
J. Bradley Layton, Lauren Peetluk, Hui Lee Wong, Yixin Jiao, Djeneba Audrey Djibo, Christine Bui, Patricia C. Lloyd, Joann F. Gruber, Michael Miller, Rachel P. Ogilvie, Jie Deng, Ron Parambi, Jennifer Song, Lisa B. Weatherby, An-Chi Lo, Kathryn Matuska, Michael Wernecke, Tainya C. Clarke, Sylvia Cho, Elizabeth J. Bell, John D. Seeger, Grace Wenya Yang, Dóra Illei, Richard A. Forshee, Steven A. Anderson, Cheryl N. McMahill-Walraven, Yoganand Chillarige, Kandace L. Amend, Mary S. Anthony, Azadeh Shoaibi
Publikováno v:
Vaccine: X, Vol 16, Iss , Pp 100447- (2024)
Background: Monovalent booster/additional doses of COVID-19 vaccines were first authorized in August 2021 in the United States. We evaluated the real-world effectiveness of receipt of a monovalent booster/additional dose of COVID-19 vaccine compared
Externí odkaz:
https://doaj.org/article/24a425573ed6479eb8e9ad2ca557699a
Autor:
F. Scott Dahlgren, David K. Shay, Hector S. Izurieta, Richard A. Forshee, Michael Wernecke, Yoganand Chillarige, Yun Lu, Jeffrey A. Kelman, Carrie Reed
Publikováno v:
Epidemics, Vol 26, Iss , Pp 23-31 (2019)
Using Medicare claims data on prescriptions of oseltamivir dispensed to people 65 years old and older, we present a descriptive analysis of patterns of influenza activity in the United States for 579 core-based statistical areas (CBSAs) from the 2010
Externí odkaz:
https://doaj.org/article/793440d32107498da5950d1362c32156
Autor:
Hui-Lee Wong, Rongmei Zhang, Bradley Lufkin, Yuhui Feng, An-Chi Lo, Manzi Ngaiza, Michael Wernecke, Qin Ryan, Amarilys Vega, Thomas E. MaCurdy, Jeffrey A. Kelman, David J. Graham
Publikováno v:
Drugs & Therapy Perspectives. 39:29-39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9ec21cfce8bd4120f389da1d2f346e9
https://doi.org/10.1007/s40267-022-00969-9
https://doi.org/10.1007/s40267-022-00969-9
Autor:
Angela K. Shen, Rob Warnock, Stephaeno Brereton, Stephen McKean, Michael Wernecke, Steve Chu, Jeffrey A. Kelman
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 8, Pp 1848-1852 (2018)
Older adults are at great risk of developing serious complications from seasonal influenza. We explore vaccination coverage estimates in the Medicare population through the use of administrative claims data and describe a tool designed to help shape
Externí odkaz:
https://doaj.org/article/46aaadbb22c4471899fceec2ae99e094
Autor:
Yun Lu, Arnstein Lindaas, Hector S Izurieta, Myrna Cozen, Mikhail Menis, Xiangyu Shi, Whitney Steele, Michael Wernecke, Yoganand Chillarige, Jeffrey A Kelman, Richard A Forshee
This retrospective study utilized healthcare claims data to investigate the incidence, patient demographics, and concurrent diagnoses associated with long COVID in the U.S. Medicare population. Nearly 194,000 (0.6%) beneficiaries had post-COVID condi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b50d63a7f904815382e06569e292e8bc
https://doi.org/10.1101/2023.03.07.23286107
https://doi.org/10.1101/2023.03.07.23286107
Autor:
Steven Kozlowski, Natasha Flowers, Andrew Kwist, Sarah K. Dutcher, Michael Wernecke, Jeffrey A. Kelman, David J. Graham
Publikováno v:
Journal of General Internal Medicine. 37:4292-4294
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0af7e77c75e8918c61325022ca7e60c
https://doi.org/10.1007/s11606-022-07670-7
https://doi.org/10.1007/s11606-022-07670-7
Autor:
Yixin Jiao, Yun Lu, Yue Wu, Hector S. Izurieta, Richard A. Forshee, Michael Wernecke, Yoganand Chillarige, David J. Graham, Jeffrey A. Kelman, Jing Wang, Mikhail Menis
Publikováno v:
The Journal of Infectious Diseases
BackgroundWe evaluated prevaccine pandemic period COVID-19 death risk factors among nursing home (NH) residents.MethodsIn a retrospective cohort study covering Medicare fee-for-service beneficiaries aged ≥65 years residing in US NHs, we estimated a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::228390a1436da4e66ea62d87acfa9c14
https://doi.org/10.1093/infdis/jiab515
https://doi.org/10.1093/infdis/jiab515
Autor:
Jeffrey A. Kelman, Michael Wernecke, Thomas E. MaCurdy, Kerry J. Welsh, Arnstein Lindaas, Deepa Arya, Julie Loc, Michael Lu, Ravi Goud, Yoganand Chillarige, Deborah L Thompson
Publikováno v:
Vaccine. 39:5368-5375
Background Anaphylaxis is a rare, serious allergic reaction. Its identification in large healthcare databases can help better characterize this risk. Objective To create an ICD-10 anaphylaxis algorithm, estimate its positive predictive values (PPVs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecb06df87eae679455350f7d50c1368a
https://doi.org/10.1016/j.vaccine.2021.08.004
https://doi.org/10.1016/j.vaccine.2021.08.004
Autor:
Andrew D. Mosholder, Yong Ma, Sandia Akhtar, Gerald D. Podskalny, Yuhui Feng, Hai Lyu, Jiemin Liao, Yuqin Wei, Michael Wernecke, Kira Leishear, Lorene M. Nelson, Thomas E. MaCurdy, Jeffrey A. Kelman, David J. Graham
Publikováno v:
The American journal of psychiatry. 179(8)
Pimavanserin, a serotonin 5-HTThis was a retrospective new-user cohort study of Medicare beneficiaries with Parkinson's disease initiating pimavanserin (N=3,227) or atypical antipsychotics (N=18,442) from April 2016 to March 2019. All-cause mortality
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25de2db9c8f5be33cf72619d31d278a6
https://pubmed.ncbi.nlm.nih.gov/35702829
https://pubmed.ncbi.nlm.nih.gov/35702829